Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 11 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 8377945

    Small molecule inhibitors of spleen tyrosine kinase (SYK)

    Rigel Pharmaceuticals, Inc. · Granted Feb 19, 2013 · Expires Feb 14, 2033

    granted
  2. US 8377924

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Feb 19, 2013 · Expires Feb 14, 2033

    granted
  3. US 8372415

    Wet granulation using a water sequestering agent

    Rigel Pharmaceuticals, Inc. · Granted Feb 12, 2013 · Expires Feb 7, 2033

    granted
  4. US 8362235

    Carboxamide compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Jan 29, 2013 · Expires Jan 24, 2033

    granted
  5. US 8349838

    Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jan 8, 2013 · Expires Jan 3, 2033

    granted
  6. US 8343954

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Jan 1, 2013 · Expires Dec 27, 2032

    granted
  7. US 8334297

    2,4-pyrimidinediamine compounds for treatment of inflammatory disorders

    Rigel Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted
  8. US 8334296

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted
  9. US 8324200

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  10. US 8314107

    Carboxamide compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Nov 20, 2012 · Expires Nov 15, 2032

    granted
  11. US 8314093

    2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases

    Rigel Pharmaceuticals, Inc. · Granted Nov 20, 2012 · Expires Nov 15, 2032

    granted
  12. US 8309566

    Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

    Rigel Pharmaceuticals, Inc. · Granted Nov 13, 2012 · Expires Nov 8, 2032

    granted
  13. US 8304422

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Nov 6, 2012 · Expires Nov 1, 2032

    granted
  14. US 8299087

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted
  15. US 8288382

    Diaminothiazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 16, 2012 · Expires Oct 11, 2032

    granted
  16. US 8278299

    Pyrimidinediamine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 2, 2012 · Expires Sep 27, 2032

    granted
  17. US 8268851

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Sep 18, 2012 · Expires Sep 13, 2032

    granted
  18. US 8263122

    Wet granulation using a water sequestering agent

    Rigel Pharmaceuticals, Inc. · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  19. US 8246984

    Formulation of insoluble small molecule therapeutics in lipid-based carriers

    Rigel Pharmaceuticals, Inc. · Granted Aug 21, 2012 · Expires Aug 16, 2032

    granted
  20. US 8227455

    Methods of treating cell proliferative disorders

    Rigel Pharmaceuticals, Inc. · Granted Jul 24, 2012 · Expires Jul 19, 2032

    granted
  21. US 8211889

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 3, 2012 · Expires Jun 28, 2032

    granted
  22. US 8211888

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 3, 2012 · Expires Jun 28, 2032

    granted
  23. US 8193197

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Jun 5, 2012 · Expires May 31, 2032

    granted
  24. US 8193181

    Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine

    Rigel Pharmaceuticals, Inc. · Granted Jun 5, 2012 · Expires May 31, 2032

    granted